Answers are grounded in this paper and cite their sources.
Case report demonstrates effective treatment for high-risk MDS patients unfit for transplantation, suggesting new therapeutic options.
The only treatment option for high-risk MDS patients unfit for transplantation is continuous treatment with a hypomethylating agent (HMA). In this context, some new combination HMA regimens and other drugs with different mechanisms of action have been developed recently; however, no breakthroughs have been made. In our clinical practice, we have gradually explored various new methods—induction therapy with a modified VIALE-A (VA) regimen and an alternating regimen of modified VA and VHAG for the consolidation period. Some patients who were persistently positive for MRD were treated with HLA-mismatched umbilical cord blood, and patients with poor hematopoietic recovery additionally received mesenchymal stem cells infusion. Together, these treatments showed good efficacy. Here, the total treatment process for a typical patient is described, and a review of the literature is provided.
No takes yet. Share an insight, caveat, or question.
Qixin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: